Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China flag China · Delayed Price · Currency is CNY
9.35
-0.05 (-0.53%)
Jun 9, 2026, 3:04 PM CST
Market Cap12.41B -15.5%
Revenue (ttm)5.42B +2.1%
Net Income380.47M -41.3%
EPS0.26 -41.3%
Shares Out 1.47B
PE Ratio36.06
Forward PE16.12
Dividend0.15 (1.54%)
Ex-Dividend Daten/a
Volume3,695,500
Open9.44
Previous Close9.40
Day's Range9.28 - 9.52
52-Week Range9.28 - 14.34
Beta0.30
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Sector Healthcare
Founded 1998
Employees 2,150
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002399
Full Company Profile

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial Statements